Business
Oncology Pharma Research and Vision
Oncology Pharma Research and Vision.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics. The Company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the fields of oncology and therapeutics with leadership to identify, negotiate and amalgamate "best in class" research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.The Company's long-range strategy involves getting our licensed products through initial phases of development and finding the appropriate path to commercial success and value creation for our stakeholders. In our initial phases we look to pediatrics and orphan drug designation as the capital outlay is projected to be significantly lower than traditional drug development programs and there is a high need for improved therapies for rare cancers with the potential for Oncology Pharma to positively impact these patients worldwide. The initial drug product being developed is a nanoemulsion of dactinomycin. Dactinomycin was approved by the FDA more than 50 years ago but has been limited in its utility due to severe toxic side-effects at effective doses. Oncology Pharma believes the novel formulation currently in development can overcome this limitation by creating a safer and potentially more effective drug formulation. This formulation may also enable greater accumulation of the drug at the tumor site, potentially increasing its tumor-kill effectiveness while simultaneously sparing healthy tissues.Studies and research have commenced. Initial feasibility work for this proprietary nanoemulsion of dactinomycin is currently underway. To date, initial formulations have demonstrated a high level of drug encapsulation and an appropriate time-release profile. Releasing dactinomycin over time following administration lowers the maximum concentration of available drug at any given time. A lower drug concentration in the blood should lead to fewer and less severe side effects, resulting in a dacti...